Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2020

September 2020 | 192 pages | ID: I5FE2201B82EN
Global Markets Direct

Abstracts

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2020, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.
H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 5, 1, 21, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 4 and 1 molecules, respectively.
Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Influenza A Virus, H5N1 Subtype Infections - Overview
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment
Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abivax SA, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by AIM ImmunoTech Inc, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by AusBio Ltd, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Pipeline by CHO Pharma Inc, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2020
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Abivax SA
Abzyme Therapeutics LLC
AIM ImmunoTech Inc
Akshaya Bio Inc
Altimmune Inc
Aphios Corp
AusBio Ltd
BiondVax Pharmaceuticals Ltd
Chicago Biosolutions Inc
CHO Pharma Inc
Cocrystal Pharma Inc
Curevac AG
CytoAgents Inc
Declion Pharmaceuticals Inc
FluGen Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
Gamma Vaccines Pty Ltd
Global BioLife Inc Ltd
Greffex Inc
i2 Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Medicago Inc
Medigen Inc
NanoViricides Inc
New Amsterdam Sciences Inc
NuGenerex Immuno-Oncology Inc
PeptiDream Inc
Pneumagen Ltd
Replikins Ltd
Seqirus Ltd
Shionogi & Co Ltd
TechnoVax Inc
Tria Bioscience Corp
Vacthera BioTech GmbH
Vaxart Inc
Vaxine Pty Ltd
Virion Biotherapeutics